I
Immunovant
Developing transformative therapies for autoimmune diseases with the goal of redefining outcomes for those affected by these conditions
About Immunovant
Immunovant is a biopharmaceutical company focused on developing innovative therapies for autoimmune diseases. These diseases occur when the immune system mistakenly attacks the body's own healthy tissues, affecting specific organs and broader bodily systems. Immunovant aims to provide transformative treatments that enable patients to lead normal lives. The company primarily serves patients suffering from autoimmune conditions, operating within the healthcare and biotechnology markets. Immunovant's business model revolves around the research, development, and commercialization of novel therapeutic solutions. Revenue is generated through the sale of these therapies, as well as potential partnerships and collaborations with other pharmaceutical companies. The company is committed to advancing its pipeline of drug candidates through rigorous clinical trials and regulatory approvals, ensuring safety and efficacy for patients. Immunovant's leadership team brings extensive experience from top-tier pharmaceutical companies, driving the company's mission to redefine outcomes for tens of thousands of people affected by autoimmune diseases.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2018
- Headquarters
- New York City, United States
- Listing
- IPO 2019
- Employees
- 315
- Open positions
- 5
- Dealroom signal
- 29.4/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Verified Unicorns and $1B Exits, Post IPO $1B, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | Dec 2025 | $550M | — | Roivant Sciences | ↗ |
| PRIVATE PLACEMENT VCOther financing | Jan 2025 | $450M | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $0 | — | −$532M | — |
| 2025 | $0 | — | −$438M | — |
| 2024 | $0 | — | −$257M | — |
| 2023 | $0 | — | −$198M | — |
| 2022 | — | — | −$156M | — |
| 2021 | — | — | −$108M | — |
| 2020 | — | — | −$66M | — |
Growth signals
Latest recorded traffic for Immunovant is 9.4K monthly website visits, down 6% over the last three months. Immunovant's team declined 10.8% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
BVF Partners
Roivant Sciences
HanAll Biopharma
RTW Investments
Series B and later5 investors entered at this stage
Frazier Healthcare Partners
Commodore Capital
TCGX
Deep Track Capital
Logos Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Immunovant on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Immunovant’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.